Solid lipid nanoparticles carrying oligonucleotides inhibit vascular endothelial growth factor expression in rat glioma models

Journal of Nanoneuroscience

Volumn 1, Issue 1, 2009, Pages 65-74

  Brioschi, Andrea M ^a   Calderoni, Sara ^a   Pradotto, Luca G ^a   Guido, Marilena ^b   Strada, Alberto ^a   Zenga, Francesco ^b   Benech, Carlo Alberto ^b   Benech, Franco ^b   Serpe, Loredana ^b   Zara, Gian Paolo ^b   Musicanti, Claudia ^c   Ducati, Alessandro ^b   Gasco, Maria Rosa ^c   Mauro, Alessandro ^a,b  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c NANOVECTOR S R L   (Italy)

Author keywords

Antisense oligonucleotides; C6 glioma cells; Glioma; Solid lipid nanoparticles; Vascular endothelial growth factor

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; DRUG CARRIER; SOLID LIPID NANOPARTICLE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG UPTAKE; GLIOMA; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RAT;

EID: 75449112144     PISSN: 19390637     EISSN: 19390653     Source Type: Journal    
DOI: 10.1166/jns.2009.007     Document Type: Article

References (62)

1. Bacic M, Edwards NA, Merrill MJ (1995) Differential expression of vascular endothelial growth factor (vascular permeability factor) forms in rat tissues. Gro wth Factors 12:11.
2. Barratt G (2003) Colloidal drug carriers: achievements and perspectives. Cell Mol Life Science 60:21.
3. Birner P, Piribauer M, Fischer I, Gatterbauer B, Marosi C, Ambros PF, Ambros IM, Bredel M, Oberhuber G, Rossler K, Budka H, Harris AL, Hainfellern JA (2003) Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol 13:133.
4. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C (2007) Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev 59:454.
5. Breyer R, Hussein S, Radu DL, Putz KM, Gunia S, Hecker H, Samii M, Walter GF, Stan AC (2000) Disruption of intracerebral progression of C6 rat glioblastoma by in vivo treatment with anti-CD44 monoclonal antibody. J Neurosurg 92:140.
6. Cavalli R, Caputo O, Gasco MR (2000) Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur J Pharm Sci 10:305.
7. Cavalli R, Caputo O, Carlotti ME, Trotta M, Scarnecchia C, Gasco MR (1997) Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int J Pharm 148:47.
8. DeAngelis LM (2001) Brain tumors. N Engl J Med 344:114.
9. Farhadi MR, Capelle HH, Erber R, Ullrich A, Vajkoczy P (2005) Combined inhibition of vascular endothelial growth factor and plateletderived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas. J Neurosurg 102:363.
10. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endoc Rev 18:4.
11. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669.
12. Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, Jain K (2001) Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 61:6020.
13. Fundarò A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR (2000) Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after IV administration to rats. Pharmacol Res 42:337.
14. Gaidamakova EK, Backer MV, Backer JM (2001) Molecular vehicle for target-mediated delivery of therapeutics and diagnostics. J Control Release 74:341.
15. Gasco MR (1997) Solid lipid nanospheres from warm microemulsions. Pharm Technol Eur 9:52.
16. Gasco MR (2001) Solid lipid nanoparticles for drug delivery. Pharm Technol Eur 13:32.
17. Gasco MR (2007) Lipid nanoparticles: perspectives and challenges. Adv Drug Deliv Rev 59:377.
18. Ikeda E, Achen MG, Breier G, Risau W (1995) Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor. J Biol Chem 270:19761.
19. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumors. Nat Rev Neurosci 8:610.
20. Jansen M, de Witt Hamer PC, Witmer AN, Troost D, van Noorden CJF (2004) Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. Brain Res Rev 45:143.
21. Johansson M, Brannstrom T, Bergenheim AT, Henriksson R (2002) Spatial expression of VEGF-A in human glioma. J Neurooncol 59:1.
22. 165 overexpression enhances tumorigenicity in U251 MG but not in NG-1 glioma cells. Cancer Res 62:1854.
23. Ke LD, Shi YX, Im SA, Chen X, Yung WK (2000) The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity in human glioma cell lines. Clin Cancer Res 6:2562.
24. Kim WJ, Yockman JW, Lee M, Jeong JH, Kim Y-H, Kim SW (2005) Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for antiangiogenesis. J Control Release 106:224.
25. Koziara JM, Lockman PR, Allen DD, Mumper RJ (2006) The bloodbrain barrier and brain drug delivery. J Nanosci Nanotechnol 6:2712.
26. Kreuter J (2001) Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47:65.
27. Krum JM, Rosenstein JM (1998) VEGF mRNA and its receptor Flt-1 are expressed in reactive astrocytes following neural grafting and tumor cell implantation in the adult CNS. Exp Neurol 154:57.
28. Lamszus K, Ulbricht U, Matschke J, Brockmann MA, Fillbrandt R, Westphal M (2003) Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin Cancer Res 9:1399.
29. Lu W, Zhang Y, Tan Y-Z, Hu K-L, Jiang X-G, Fu S-K (2005) Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J Control Release 107:428.
30. Mehnert W, Mäder K (2001) Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 47:165.
31. Miglietta A, Cavalli R, Bocca C, Gabriel L, Gasco MR, (2000) Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int J Pharm 210:61.
32. Mischel PS, Cloughesy TF (2003) Targeted molecular therapy of GBM. Brain Pathol 13:52.
33. Müller RH (2007) Lipid nanoparticles: recent advances. Adv Drug Deliv Rev 59:375.
34. Müller RH, Keck CM (2004) Challenges and solutions for the delivery of biotech drugs: a review of drug nanocrystal technology and lipid nanoparticles. J Biotech 113:151.
35. Müller RH, Olbrich C (1999) Solid lipid nanoparticles: Phagocytic uptake, in vitro cytotoxicity and in vitro biodegradation. Pharm Ind 61:564.
36. Müller RH, Mäder K, Gohla S (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery: a review of the state of the art. Eur J Pharm Biopharm 50:161.
37. Müller RH, Rühl D, Runge S, Schulze-Foster K, Mehnert W (1997) Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res 14:458.
38. Niola F, Evangelisti C, Campagnolo L, Massalini S, Buè MC, Mangiola A, Masotti A, Maira G, Farace MG, Ciafrè SA (2006) A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model. Cancer Biol Ther 5:174.
39. Norden AD, Wen PY (2006) Glioma therapy in adults. Neurologist 12:279.
40. Olbrich C, Bakowsky U, Lehr CM, Müller RH, Kneuer C (2001) Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J Control Release 77:345.
41. Pardridge WM (2007) Blood-brain barrier delivery. Drug Discov Today 12:54.
42. Peira E, Marzola P, Podio V, Aime S, Sbarbati A, Gasco MR (2003) In vitro and in vivo study of solid lipid nanoparticles loaded with superparamagnetic iron oxide. J Drug Target 11:19.
43. Peoc'h M, Farion R, Hiou A, Le Bas JF, Pasquier B, Rémi C (2002) Immunohistochemical study of VEGF, angiopoietin-2 and their receptors in the neovascularization following microinjection of C6 glioma cells into rat brain. Anticancer Res 22:2147.
44. Podio V, Zara GP, Carazzone M, Cavalli R, Gasco MR (2000) Biodistribution of stealth and non-stealth solid lipid nanoparticles after intravenous administration to rats. J Pharm Pharmacol 52:1057.
45. Rich JN, Bigner DD (2004) Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 3:430.
46. Rong Y, Durden DL, Van Meir EG, Brat DJ (2006) " Pseudopalisading" necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 65:529.
47. Rosenstein JM, Krum JM (2004) New roles for VEGF in nervous tissue: beyond blood vessels. Exp Neurol 187:246.
48. Saleh M, Stacker SA, Wilks AF (1996) Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 56:393.
49. Serganova I, Doubrovin M, Vider J, Ponomarev V, Soghomonyan S, Beresten T, Ageyeva L, Serganov A, Cai S, Balatoni J, Blasberg R, Gelovani J (2004) Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Res 64:6101.
50. Serikawa T, Kikuchi A, Sugaya S, Suzuki N, Kikuchi H, Tanaka K (2006) In vitro and in vivo evaluation of novel cationic liposomes utilized for cancer gene therapy. J Control Release 113:255.
51. Tabatt K, Sameti M, Olbrich C, Müller RH, Lehr CM (2004) Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticlemediated gene transfer. Eur J Pharm Biopharm 57:155.
52. Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaya F, Zhang Z, Zangh H, Teng Q, Nicholson AC, Giannakakou P, Zhou W, Olson JJ, Pereire MM, Nicolaou KC, Van Meir EG (2005) Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor-1 pathway. Cancer Res 65:605.
53. Tiwari SB, Amiji MM (2006) A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv 3:219.
54. Toi M, Matsumoto T, Bando H (2001) Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol 2:667.
55. Tondelli L, Ricca A, Laus M, Lelli M, Citro G (1998) Highly efficient cellular uptake of c-myb antisense oligonucleotides through specifically designed polymeric nanospheres. Nucleic Acids Res 26:5425.
56. Wissing SA, Kayser O, Müller RH (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56:1257.
57. Yano A, Shingo T, Takeuchi A, Yasuhara T, Kobajashi K, Takahashi K, Muraoka K, Matsui T, Miyoshi Y, Hamada H, Date I (2005) Encapsulated vascular endothelial growth factor-secreting cell grafts have neuroprotective and angiogenic effects on focal cerebral ischemia. J Neurosurg 103:104.
58. Yasuhara T, Shingo T, Muraoka K, Wen Ji Y, Kameda M, Takeuchi A, Yano A, Nioshio S, Matsui T, Miyoshi Y, Hamada H, Date I (2005) The differences between high- and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model. Brain Res 1038:1.
59. Zara GP, Bargoni A, Cavalli R, Fundarò A, Vighetto D, Gasco MR (2002a) Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J Pharm Sci 91:1324.
60. Zara GP, Cavalli R, Bargoni A, Fundarò A, Vighetto D, Gasco MR (2002b) Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentration of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target 10:327.
61. Zara GP, Cavalli R, Fundarò A, Bargoni A, Caputo O, Gasco MR (1999) Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol Res 40:281.
62. Zhou YH, Tan F, Hess KR, Yung WK (2003) The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res 9:3369.